Imprimis to offer low-cost alternative to Restasis for dry eye disease

Imprimis Pharmaceuticals is set to provide its cyclosporine-based formulations as customisable and potential low-cost alternatives to Restasis indicated for dry eye disease.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news